KD Logo

Blueprint Medicines Corp [BPMC] Insider Carter Percy H. sells 4,000 Shares – Latest News


In a filing, Blueprint Medicines Corp revealed its CHIEF SCIENTIFIC OFFICER Carter Percy H. unloaded Company’s shares for reported $0.42 million on Jun 05 ’24. In the deal valued at $105.13 per share,4,000 shares were sold. As a result of this transaction, Carter Percy H. now holds 41,895 shares worth roughly $4.36 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Then, Hewes L. Becker sold 2,424 shares, generating $254,302 in total proceeds. Upon selling the shares at $104.91, the CHIEF MEDICAL OFFICER now owns 29,514 shares.

Before that, Hewes L. Becker sold 4,922 shares. Blueprint Medicines Corp shares valued at $523,848 were divested by the CHIEF MEDICAL OFFICER at a price of $106.43 per share. As a result of the transaction, Hewes L. Becker now holds 31,938 shares, worth roughly $3.32 million.

Stephens initiated its Blueprint Medicines Corp [BPMC] rating to an Overweight in a research note published on May 14, 2024; the price target was $140. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who increased its forecast for the stock in early May from “an Underperform” to “a Market perform”. Oppenheimer also remained covering BPMC and has increased its forecast on October 27, 2023 with a “an Outperform” recommendation from previously “Perform” rating. Needham maintained its rating on August 21, 2023. It rated BPMC as “a Buy”.

Price Performance Review of BPMC

On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 0.67% to $104.03. Over the last five days, the stock has lost -0.77%. Blueprint Medicines Corp shares have risen nearly 12.78% since the year began. Nevertheless, the stocks have risen 83.77% over the past one year. While a 52-week high of $111.02 was reached on 05/14/24, a 52-week low of $43.89 was recorded on 02/14/24. SMA at 50 days reached $98.59, while 200 days put it at $77.79. A total of 0.57 million shares were traded, compared to the trading of 0.38 million shares in the previous session.

Levels Of Support And Resistance For BPMC Stock

The 24-hour chart illustrates a support level at 101.66, which if violated will result in even more drops to 99.30. On the upside, there is a resistance level at 105.40. A further resistance level may holdings at 106.78. The Relative Strength Index (RSI) on the 14-day chart is 53.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 52.30%. Stochastics %K at 46.72% indicates the stock is a holding.

Most Popular